Amylyx Pharmaceuticals (AMLX) stock: insider trades, news & valuation
Net sellingShare price and insider trades
Amylyx Pharmaceuticals insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $152K and 6 sold $10.1M of AMLX stock on the open market.
Get emailed when insiders cluster-buy stocks like AMLX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
AMLX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $831K | 1 |
| Q3 2026 | — | 0 | $3.5M | 12 |
| Q2 2026 | $51K | 1 | — | 0 |
| Q1 2026 | — | 0 | $5.7M | 17 |
| Q4 2025 | $101K | 1 | $94K | 1 |
| Q3 2025 | — | 0 | $1.3M | 7 |
Valuation, profit and volume
Summary
Over the past 12 months, 1 Amylyx Pharmaceuticals, Inc. insider reported open-market purchases totaling $152K, while 6 insiders reported sales totaling $10.1M. Among insiders with enough purchase history to measure, Karen Firestone (Director) has the highest Insider Score at 100. 3 of 38 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
AMLX earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 6, 2026 | +18.1% | Sold $539K | +4.4%S&P +0.5% | +49.4% |
| May 7, 2026 | -8.7% | None | -8.3%S&P +0.5% | -9.6% |
| Mar 3, 2026 | +8.4% | Sold $1.8M | -1.6%S&P -0.2% | -0.7% |
| Nov 6, 2025 | -13.4% | None | -7.0%S&P -1.0% | +15.4% |
| Aug 7, 2025 | +4.1% | None | -6.7%S&P +0.7% | +33.5% |
| May 8, 2025 | -1.0% | None | -5.3%S&P +0.6% | +15.6% |
| Mar 4, 2025 | -19.4% | None | +12.0%S&P -0.1% | +2.1% |
| Nov 7, 2024 | +37.3% | None | +7.7%S&P +1.2% | -23.3% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 7SEC | George M Milne Jr.Director | Sell Plan | 30,000782,881 held (−4%) | $27.70 | $831K | +1.6% | — |
| Sep 14SEC | Joshua B CohenCEO | Sell | 29,5453,614,042 held (−1%) | $32.16 | $950K | -12.5% | — |
| Sep 14SEC | Justin B. KleeCEO | Sell | 29,0253,614,495 held (−1%) | $32.13 | $933K | -12.4% | — |
| Sep 14SEC | James M FratesCFO | Sell | 9,768234,667 held (−4%) | $32.27 | $315K | -12.8% | — |
| Sep 14SEC | Gina MazzarielloGeneral Counsel | Sell | 9,525190,849 held (−5%) | $32.46 | $309K | -13.3% | — |
| Sep 14SEC | Camille L BedrosianChief Medical Officer | Sell | 7,947280,145 held (−3%) | $32.21 | $256K | -12.6% | — |
| Sep 14SEC | Camille L BedrosianChief Medical Officer | Sell | 2,081278,064 held (−1%) | $33.09 | $69K | -15.0% | — |
| Sep 14SEC | Justin B. KleeCEO | Sell | 1,4393,613,056 held (−0%) | $33.16 | $48K | -15.1% | — |
| Sep 14SEC | James M FratesCFO | Sell | 1,042233,625 held (−0%) | $33.23 | $35K | -15.3% | — |
| Sep 14SEC | Joshua B CohenCEO | Sell | 9193,613,123 held (−0%) | $33.15 | $30K | -15.1% | — |
| Sep 14SEC | Gina MazzarielloGeneral Counsel | Sell | 11190,838 held (−0%) | $33.34 | $367 | -15.6% | — |
| Jul 13SEC | Gina MazzarielloGeneral Counsel | Sell Plan | 15,000194,090 held (−7%) | $18.32 | $275K | +53.6% | — |
| Jul 13SEC | Gina MazzarielloGeneral Counsel | Sell Plan | 15,000179,090 held (−8%) | $17.61 | $264K | +59.8% | — |
| May 26SEC | Karen FirestoneDirector | Buy | 3,80066,900 held (+6%) | $13.51 | $51K | +108.3% | 100 |
| Mar 4SEC | Joshua B CohenCEO | Sell | 29,2823,334,683 held (−1%) | $14.48 | $424K | +94.3% | — |
| Mar 4SEC | Justin B. KleeCEO | Sell | 29,2823,334,616 held (−1%) | $14.47 | $424K | +94.5% | — |
| Mar 4SEC | James M FratesCFO | Sell | 7,909165,638 held (−5%) | $14.52 | $115K | +93.8% | — |
| Mar 4SEC | Gina MazzarielloGeneral Counsel | Sell | 6,844134,430 held (−5%) | $14.52 | $99K | +93.8% | — |
| Mar 4SEC | Camille L BedrosianChief Medical Officer | Sell | 6,461169,295 held (−4%) | $14.58 | $94K | +93.0% | — |
| Feb 25SEC | Gina MazzarielloGeneral Counsel | Sell | 3,419141,274 held (−2%) | $14.14 | $48K | +99.0% | — |
| Feb 4SEC | Justin B. KleeCEO | Sell | 15,5003,363,898 held (−0%) | $14.69 | $228K | +91.6% | — |
| Feb 4SEC | Joshua B CohenCEO | Sell | 15,5003,363,965 held (−0%) | $14.68 | $228K | +91.7% | — |
| Feb 4SEC | James M FratesCFO | Sell | 3,557173,547 held (−2%) | $14.65 | $52K | +92.1% | — |
| Feb 4SEC | Gina MazzarielloGeneral Counsel | Sell | 3,448144,693 held (−2%) | $14.65 | $51K | +92.1% | — |
| Jan 20SEC | Joshua B CohenCEO | Sell | 136,1933,378,621 held (−4%) | $13.59 | $1.9M | +107.1% | — |
| Jan 20SEC | Justin B. KleeCEO | Sell | 136,1933,378,546 held (−4%) | $13.58 | $1.8M | +107.2% | — |
| Jan 20SEC | Justin B. KleeCEO | Sell | 1,9953,379,398 held (−0%) | $13.89 | $28K | +102.6% | — |
| Jan 20SEC | Joshua B CohenCEO | Sell | 1,9743,379,465 held (−0%) | $13.83 | $27K | +103.5% | — |
| Jan 8SEC | Justin B. KleeCEO | Sell | 7,7153,317,586 held (−0%) | $11.09 | $86K | +153.7% | — |
| Jan 8SEC | Joshua B CohenCEO | Sell | 7,7153,317,632 held (−0%) | $11.09 | $86K | +153.7% | — |
| Jan 8SEC | James M FratesCFO | Sell | 3,326177,104 held (−2%) | $11.11 | $37K | +153.3% | — |
| Dec 23SEC | Karen FirestoneDirector | Buy | 8,10063,100 held (+15%) | $12.45 | $101K | +126.0% | 100 |
| Dec 3SEC | Camille L BedrosianChief Medical Officer | Sell | 6,580175,756 held (−4%) | $14.35 | $94K | +96.1% | — |
| Oct 2SEC | Justin B. KleeCEO | Sell | 29,7753,325,501 held (−1%) | $14.37 | $428K | +95.8% | — |
| Oct 2SEC | Joshua B CohenCEO | Sell | 29,7333,325,547 held (−1%) | $14.34 | $426K | +96.2% | — |
| Oct 2SEC | Camille L BedrosianChief Medical Officer | Sell | 12,039182,336 held (−6%) | $14.58 | $176K | +93.0% | — |
| Oct 2SEC | James M FratesCFO | Sell | 10,558280,430 held (−4%) | $14.65 | $155K | +92.1% | — |
| Oct 2SEC | Gina MazzarielloGeneral Counsel | Sell | 8,828148,141 held (−6%) | $14.58 | $129K | +93.0% | — |
| Oct 2SEC | Justin B. KleeCEO | Sell | 2003,325,301 held (−0%) | $15.01 | $3K | +87.5% | — |
| Oct 2SEC | Joshua B CohenCEO | Sell | 2003,325,347 held (−0%) | $15.00 | $3K | +87.6% | — |
Insiders at Amylyx Pharmaceuticals, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Justin B. KleeCEO | — | $4.0M | Sep 14, 2026 | — |
| Joshua B CohenCEO | — | $4.0M | Sep 14, 2026 | — |
| Gina MazzarielloGeneral Counsel | — | $1.2M | Sep 14, 2026 | — |
| George M Milne Jr.Director | — | $831K | Oct 7, 2026 | — |
| James M FratesCFO | — | $708K | Sep 14, 2026 | — |
| Camille L BedrosianChief Medical Officer | — | $689K | Sep 14, 2026 | — |
| Karen FirestoneDirector | $152K | — | May 26, 2026 | 100 |
AMLX stock: common questions
Are Amylyx Pharmaceuticals, Inc. insiders buying AMLX stock?
In the past 12 months, 1 insiders reported open-market purchases of AMLX worth $152K. The latest was Director Karen Firestone bought $51K of AMLX at $13.51.
Are Amylyx Pharmaceuticals, Inc. insiders selling AMLX stock?
6 insiders reported sales worth $10.1M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is AMLX's 52-week range?
Over the past year AMLX has traded between $11.38 and $39.66. It last closed at $28.14 on Oct 9, 2026.